Clinical trials: Lenalidomide, completed
Myeloma
Maintenance Therapy Using Lenalidomide in Myeloma
Maintenance treatment of myeloma.
- Trial name
- IFM2005-02 (NCT00430365)
- Testing
- lenalidomide
- Where
- 77 sites in Belgium, France and 1 more
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Follicular Lymphoma
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular…
- Trial name
- R2-CHOP2 (NCT01393756)
- Testing
- Lenalidomide and R-CHOP
- Where
- 24 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Lymphoma Academic Research Organisation
Healthy
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
To find out if the blood level of lenalidomide can be changed when a drug that prevents p-glycoprotein (a protein naturally present in the body that helps carry substances across cell membranes that is found in many parts of the…
- Trial name
- NCT01712828
- Testing
- Lenalidomide, Quinidine, Temsirolimus
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation.
- Trial name
- NCT02521714
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Prostate Cancer
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
The primary objectives of the study are: To evaluate feasibility, safety and tolerance of 6 months administration of Revlimid at 5mg/day and 25mg/day, given orally in subjects with prostate cancer with evidence of biochemical…
- Trial name
- NCT00348595
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy, Male
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg) when administered a single-dose to healthy male…
- Trial name
- NCT03208218
- Testing
- SYP-1512, Revlimid cap
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation